Cerus Corporation's Q2 2025: Navigating Contradictions in Supply Dynamics, Revenue Growth, and Demand Expectations

Revenue Growth and Product Demand:
- Cerus reported record product revenue of $52.4 million for Q2, up 16% year-over-year.
- The growth was driven by increasing customer demand for INTERCEPT's fibrinogen complex and continued platelet sales growth, particularly in the U.S. and EMEA region.

INTERCEPT Fibrinogen Complex (IFC) Sales:
- IFC sales in the U.S. reached $5.6 million in Q2, compared to $2 million in the prior year period, representing a significant increase.
- The growth was attributed to the increasing availability and utility of IFC in managing critically bleeding patients, which is being acknowledged across the U.S.

Regulatory Progress and Market Expansion:
- Cerus's red blood cell program in Europe is advancing with the notified body completing clinical module review and transferring the dossier to the State Institute for Drug Control.
- The expansion of the CE Mark submission to cover all patient indications for red cell transfusion opens up broader market potential and reduces initial operational constraints on blood centers.

International Market Penetration:
- Cerus is expanding its footprint in the Middle East, with strong platelet growth in Saudi Arabia, Kuwait, and the UAE, alongside deeper platelet penetration in existing markets.
- This growth is supported by the successful integration of the INT200 Illuminator and strategic partnerships with blood centers and regulatory bodies.